Multiple Sclerosis Drugs - Greece

Greece

In Greece, the Multiple Sclerosis Drugs market is expected to see a projected revenue of US$26.61m in 2024.
This figure is projected to grow at an annual rate of 0.38% between 2024 and 2029, reaching a market volume of US$27.12m by 2029.
It is worth noting that in a global comparison, United States is expected to generate the highest revenue in this market, with an estimated US$11,770.00m in 2024.
The Greek market for Multiple Sclerosis Drugs is experiencing a surge in demand due to the increasing prevalence of the disease among the aging population.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Greece has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Greece prefer drugs that are effective in reducing the progression of the disease and improving their quality of life. They also prefer drugs that are affordable and easily accessible.

Trends in the market: The Multiple Sclerosis Drugs market in Greece has been growing due to the increasing prevalence of the disease in the country. The market has also been driven by the introduction of new drugs that are more effective in treating the disease and have fewer side effects. In addition, the market has been boosted by the increasing use of immunomodulatory therapies that help to slow down the progression of the disease.

Local special circumstances: The Greek healthcare system has been facing significant challenges in recent years due to the economic crisis that has affected the country. As a result, there have been significant cuts in healthcare spending, which has affected the availability of drugs for patients suffering from Multiple Sclerosis. However, the government has been taking steps to address this issue by increasing funding for healthcare and improving access to drugs for patients.

Underlying macroeconomic factors: The Greek economy has been recovering in recent years, which has had a positive impact on the healthcare sector. The government has been investing more in healthcare, which has led to an increase in the availability of drugs for patients suffering from Multiple Sclerosis. In addition, the aging population in Greece has led to an increase in the prevalence of the disease, which has driven growth in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.